Emergent BioSolutions (NYSE:EBS) Price Target Raised to $12.00

Emergent BioSolutions (NYSE:EBS) had its price target lifted by Benchmark from $8.00 to $12.00 in a research report sent to investors on Thursday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Separately, Rodman & Renshaw restated a “buy” rating and set a $16.00 price objective on shares of Emergent BioSolutions in a report on Friday, September 13th.

Emergent BioSolutions Stock Up 7.0 %

EBS traded up $0.77 during mid-day trading on Thursday, reaching $11.77. 2,168,164 shares of the stock were exchanged, compared to its average volume of 1,163,124. The company has a 50 day moving average price of $8.43 and a two-hundred day moving average price of $7.78. The stock has a market capitalization of $622.75 million, a PE ratio of -2.87 and a beta of 1.57. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.54 and a current ratio of 1.06. Emergent BioSolutions has a 1 year low of $1.42 and a 1 year high of $15.10.

Institutional Investors Weigh In On Emergent BioSolutions

Several institutional investors have recently made changes to their positions in EBS. American Century Companies Inc. grew its stake in Emergent BioSolutions by 240.9% during the second quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after acquiring an additional 623,201 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Emergent BioSolutions by 14.7% during the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock valued at $8,631,000 after purchasing an additional 436,911 shares in the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Emergent BioSolutions by 74.5% in the third quarter. Assenagon Asset Management S.A. now owns 741,552 shares of the biopharmaceutical company’s stock worth $6,192,000 after purchasing an additional 316,700 shares during the period. Federated Hermes Inc. raised its position in shares of Emergent BioSolutions by 1,314.0% in the second quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock worth $1,864,000 after buying an additional 253,960 shares in the last quarter. Finally, Marshall Wace LLP raised its position in shares of Emergent BioSolutions by 75.4% in the second quarter. Marshall Wace LLP now owns 542,813 shares of the biopharmaceutical company’s stock worth $3,702,000 after buying an additional 233,341 shares in the last quarter. Hedge funds and other institutional investors own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.